Skip to main content
Premium Trial:

Request an Annual Quote

BioNanomatrix Snags $833K in New SBIR Funding

NEW YORK (GenomeWeb News) – BioNanomatrix will use two new grants totaling $833,000 from the National Human Genome Research Institute to continue developing and evaluating its genomic nanoscale imaging and analysis platform, the company said today.

The Philadelphia-based firm said it will use the Small Business Innovation Research grant funding to prepare for planned commercial launch of the NanoAnalyzer system, which is scheduled for the second quarter of 2010.

The company said the NanoAnalyzer system will help scientists analyze individual ultra-long strands of DNA in a massively parallel format. Currently in alpha evaluation, the system will enable researchers to scan a human genome in as little as ten minutes, creating an organizational map of each sample, BioNanomatrix said.

The funding will be used for beta-site evaluation, during which researchers at different facilities will use the platform for a range of applications, including studies of genome integrity and structural variation mapping. Later in the development process, the firm said, the tool will be used for epigenetic mapping and sequence analysis projects.

"Our nanoscale technology is intended to allow researchers to directly image and analyze very long, individual intact strands of DNA at the single-molecule level, at high resolution and with very high throughputs, yielding a great deal of genomic information," BioNanomatrix President and CEO Michael Boyce-Jacino, said in a statement.

BioNanomatrix said that including these most recent supplemental grants it now has received more than $2.8 million in total Phase II NHGRI funding.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.